



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Vaccine products in the R&D pipeline have more than tripled since 2005

Worldwide vaccine sales are projected to surpass \$40 billion by 2020

- Worldwide vaccine sales grew at an average annual rate of 11.5% from 2005 to 2014, nearly double the 6% average annual growth rate for total pharmaceutical sales.
- Although 18 companies market vaccines, five companies dominated the vaccine market during the last decade, accounting for more than 80% of total worldwide sales.
- The number of vaccine products in clinical trials has grown dramatically – from 102 in 2002 to 250 in 2013.
- Vaccines accounted for 28% of all biotechnology development candidates in clinical research in 2013.
- Cancer is a major focus in new vaccine development, with the goal of increasing cancer cure rates.